Evidence map›Paper›PMID 40630959›Full record

ArticleFrontiers in immunology2025

ISGylation and E3 ubiquitin ligases: an Atlantic salmon genetic perspective.

Unni Grimholt, Hilde Sindre, Arvind Y M Sundaram

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Unni GrimholtFish Health Research Section, Norwegian Veterinary Institute, Ås, Norway.
Hilde SindreFish Health Research Section, Norwegian Veterinary Institute, Ås, Norway.
Arvind Y M SundaramFish Health Research Section, Norwegian Veterinary Institute, Ås, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In mammals, the ubiquitin-proteasomal pathway plays a key role in the host antiviral response by targeting viral genes for degradation. Here, E1-activating enzymes, E2-conjugating enzymes, and E3 ligases attach the ubiquitin chain to molecules to be functionally modified or destined for degradation. One specialized version of this pathway is performed by ISG15, a ubiquitin-like protein modifier that works through a process called ISGylation. In mammals, ISGylation involves specialized E1-E3 molecules and specialized mammalian ISG15 "deubiquitinases" also exist. Targeting host and viral proteins, ISG15 can inhibit the release of viral particles or hinder viral replication, thereby exerting strong antiviral effects. In Atlantic salmon, endothelial cells from the heart is a main target for infectious salmon anemia virus (ISAV). Results: Here, we established a new cell line from Atlantic salmon heart tissue denoted ASH2-2, which has endothelial-like characteristics and is permissive for infection with ISAV and other salmonid viruses. We used this cell line as a model to compare the effect of recombinant interferon gamma (rIFNg) and ISAV on genes potentially involved in the ubiquitin-proteasome pathway. ASH2-2 cells have a response profile matching endothelial cells and respond quickly to ISAV infection with upregulation of viral sensors such as DHX58, MDA5, and MX transcripts. Two Conclusion: In conclusion, we expand the list of teleost genes potentially involved in the ubiquitin-proteasome pathway in cells from a main target organ. Our results highlight the need for functional studies to clarify the roles of these candidates.

Indexed as

CytokinesFish DiseasesFish ProteinsIsavirusOrthomyxoviridae InfectionsSalmo salarUbiquitin-Protein LigasesUbiquitinsAnimalsCell LineEndothelial CellsInterferon-gammaCytokinesFish ProteinsInterferon-gammaUbiquitin-Protein LigasesUbiquitinsAtlantic salmonE3 ubiquitin ligasesHERCIFN gammaISAVISG15ISGylationRBR family

Identifiers

PMID40630959
PMCPMC12234341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.